Navigation Links
Catalent to Debate Logistics of Delivery and Transportation of Cell and Gene Therapies at HPCLC
Date:10/22/2019

Catalent, a global leader in clinical supply services, today announced that Ann McMahon, Program Director, Clinical Supply Services and Drug Product Technologies Integration, will participate in a panel session titled “Cell and Gene Therapy Logistics” at the upcoming Health and Personal Care Logistics Conference (HPCLC), to be held at the Gwen Hotel, Chicago, on Oct. 28-30, 2019.

The panel session, on Wednesday, Oct. 30 at 8:30 a.m., comes at a time when there is an increasing focus on individualizing patient care, and panelists will discuss the critical logistics of delivery and transportation as patient care changes; and as cell, gene and biologics therapies constitute an ever-increasing share of treatments. The panelists will also explore future transportation demands.

Ms. McMahon has over 17 years of experience in the pharmaceutical industry. Prior to joining Catalent, she was Manager, New Product Launch at West-Ward Pharmaceuticals, and also Boehringer Ingelheim. She holds a bachelor’s degree in biology/biochemistry from Ohio Northern University, Ada, Ohio; and a master’s degree in clinical pharmacology from the Ohio State University, Columbus, Ohio.

For further information, visit https://www.hpclcnet.org/.

To arrange a meeting with Ms. McMahon at the event, contact Richard Kerns at NEPR - richard@nepr.agency.

About Catalent
Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs nearly 13,000 people, including approximately 2,400 scientists, at more than 35 facilities across five continents, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com

More products. Better treatments. Reliably supplied.™

Read the full story at https://www.prweb.com/releases/catalent_to_debate_logistics_of_delivery_and_transportation_of_cell_and_gene_therapies_at_hpclc/prweb16662663.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology technology :

1. Catalent and Minerva Neurosciences Enter Commercial Supply Agreement for Schizophrenia Drug Roluperidone
2. Advantages of Singapore as a Clinical Supply Hub to be Discussed by Catalent at Accelerating Clinical Trials in Asia Conference
3. Flexible Filling and Adoption of ‘Ready-to-Use’ Technologies to be Discussed by Catalent Biologics at the Pharma Forum
4. Catalent Expert to Discuss the Importance of Formulation to Benefit Diabetes Patients at NLS Days
5. Catalent Biologics Announces Agreement to Provide Additional Production of Approved Gene Therapy Treatment for Spinal Muscular Atrophy
6. IVERIC bio Enters into Strategic Manufacturing Relationship with Catalent’s Paragon Gene Therapy for Orphan Inherited Retinal Diseases
7. Patient-Focused Drug Delivery to be Presented by Catalent at PODD
8. Lipid-Based Drug Delivery in Modern Pharmaceutical Development to be Presented by Catalent and BASF at Forthcoming Workshop
9. Catalent Biologics Announces Collaboration with Therachon, Switzerland, to Advance Clinical Development of Innovative Protein Therapy for Achondroplasia
10. Catalent Executives to Present on Clinical Trial Supply Management and Optimizing Product Development at Upcoming BioPharma Asia Conference
11. Portages Biohaven enters into exclusive formulation agreement and global license with Catalent for lead product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2020)... ... March 31, 2020 , ... ... B.V. (MBS) has developed a method using its revolutionary NEXTGENPCR endpoint thermocycler ... Combined with smaller reaction volumes, increased samples per run, and standard, affordable ...
(Date:3/27/2020)... ... March 25, 2020 , ... Enso ... centrally in the midwest for high-quality, quick-turn, board-certified reporting. In an effort ... independent, professional team that is focused on incredible quality, turnaround time and ...
(Date:3/19/2020)... ... March 18, 2020 , ... Family counsellors, marriage/couples therapists, ... rapid insight into their perceptions of events. Imagine if a couple’s counsellor could ... they could measure the level of engagement of each individual in the therapeutic ...
(Date:3/10/2020)... (PRWEB) , ... March 10, 2020 , ... Ortho Clinical ... through innovative laboratory solutions, announced its ORTHOTM Sera, ID-MTS, a suite of extended antigen ... transfusion, is cleared to run on ORTHO VISION® and ORTHO VISION® Max in the ...
Breaking Biology Technology:
(Date:3/11/2020)... LAUDERDALE, Fla. (PRWEB) , ... March 11, 2020 ... ... Accredited teleradiology and telemedicine company backed by Siemens Healthineers and several healthcare VC ... already infected over 100,000 people in over 100 countries and has caused over ...
(Date:3/5/2020)... SAN DIEGO (PRWEB) , ... March 05, 2020 ... ... Inc. today announced a strategic partnership agreement with Phoenestra GmbH to accelerate Cytonus’ ... biotech company founded in San Diego, California. Phoenestra is a biotech company located ...
(Date:3/5/2020)... ... March 05, 2020 , ... In September 2016, ... The AlphaSTEM Test™ is the first, and still only, available technology that provides ... attempt to provide information about the number and quality of therapeutic tissue stem ...
Breaking Biology News(10 mins):